Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06962800 · ClinicalTrials.gov registry record · Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

A Phase 3 study of Primary Membranous Nephropathy, sponsored by Biogen.

Recruiting
Registry status
Phase 3
Development phase
180
Enrollment target
20
Study locations

NCT06962800: Recruiting Phase 3 study of Primary Membranous Nephropathy, sponsored by Biogen.

NCT06962800 is a Phase 3 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Biogen. The registered enrollment target is 180 participants, above the 114-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (58% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06962800, a Phase 3 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Biogen.

RECRUITING
Registry status
Phase 3
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure. In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease. The main question that researchers want to answer is: * How many participants achieve a complete response after 104 weeks of treatment? * A complete response means that their urine protein levels decrease to a low level and their kidney function remains stable. Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * How many participants develop antibodies against felzartamab in the blood? * How many participants achieve a complete response after 76 weeks of treatment * How many participants have medical problems during

Conditions Studied

Primary Membranous Nephropathy

Interventions

  • DRUG Tacrolimus
  • DRUG Felzartamab
  • DRUG Standard of Care IST

Study Locations (20)

Other

  • Organización Médica de Investigación - Buenos Aires
  • CINME S.A. - Centro de Investigaciones Metabólicas - Buenos Aires
  • Hospital Italiano de Buenos Aires - Buenos Aires
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada - Buenos Aires
  • Clínica Privada Vélez Sarsfield - Córdoba

California

  • The Nephrology Group, Inc. - Fresno - Fresno
  • Academic Medical Research Institute - Los Angeles
  • UCSF Medical Center - San Francisco

New South Wales

  • Concord Hospital - Concord
  • St George Hospital - Kogarah
  • Westmead Hospital - Westmead

Michigan

  • Henry Ford Hospital- A-Basement Research Pharmacy - Detroit
  • Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS - Pontiac

Texas

  • Nephrotex Research Group - Dallas
  • University of Texas Medical Branch - League City

Alabama

  • Apogee Clinical Research, LLC - Huntsville

New York

  • James J Peters Veterans Administration Medical Center - NAVREF - PPDS - The Bronx

North Carolina

  • ECU Physicians Nephrology and Hypertension - Greenville

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2025-05-22
Est. Completion 2029-03-29
Phase Phase 3
Biogen

334 total trials

What NCT06962800 shows while recruiting

NCT06962800 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 114-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (58% higher).

The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 3 interventions - of which Tacrolimus is the first listed.

NCT06962800 names 20 study sites across 10 states, led by Other, California, New South Wales.

Frequently Asked Questions

What is clinical trial NCT06962800 about?

NCT06962800 is a clinical study titled "A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)". In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody ...

What is the current status of trial NCT06962800?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-05-22. Estimated completion is 2029-03-29.

What conditions does trial NCT06962800 study?

This clinical trial studies the following conditions: Primary Membranous Nephropathy.

What interventions are being tested in trial NCT06962800?

The interventions under investigation include: Tacrolimus (DRUG), Felzartamab (DRUG), Standard of Care IST (DRUG).

Who is sponsoring clinical trial NCT06962800?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06962800 being conducted?

This trial has 20 study locations across Alabama, California, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Membranous Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06962800's enrollment target sits among peer trials

180 1st of 8 higher than 8 of 8 other Primary Membranous Nephropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Primary Membranous Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06962800

Source: ClinicalTrials.gov NCT06962800, the US trial registry maintained by the National Library of Medicine. NCT06962800 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.